HC Wainwright Has Weak Forecast for Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Precigen in a research note issued to investors on Friday, November 15th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.01 per share for the year, down from their prior forecast of $0.02. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

Several other equities analysts have also recently issued reports on PGEN. JMP Securities lowered their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 15th. StockNews.com upgraded shares of Precigen to a “sell” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.00.

Precigen Stock Performance

Shares of PGEN opened at $0.79 on Monday. Precigen has a one year low of $0.78 and a one year high of $1.93. The firm has a market capitalization of $232.01 million, a price-to-earnings ratio of -1.44 and a beta of 1.68. The stock’s fifty day moving average is $0.92 and its 200-day moving average is $1.24.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the company. Traphagen Investment Advisors LLC acquired a new stake in shares of Precigen in the 3rd quarter valued at $29,000. Stifel Financial Corp raised its position in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares during the period. EntryPoint Capital LLC acquired a new stake in Precigen during the 1st quarter worth approximately $31,000. SG Americas Securities LLC lifted its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 13,823 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Precigen by 86.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 25,681 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.